Vaxcyte, Inc. $PCVX Position Reduced by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 9.5% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 371,550 shares of the company’s stock after selling 39,055 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Vaxcyte were worth $21,598,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in PCVX. Smartleaf Asset Management LLC boosted its stake in Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after purchasing an additional 364 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after purchasing an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after buying an additional 184 shares during the period. CIBC Private Wealth Group LLC grew its holdings in shares of Vaxcyte by 22,500.0% during the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after buying an additional 1,350 shares in the last quarter. Finally, Capital Advisors Ltd. LLC acquired a new position in Vaxcyte during the first quarter valued at $58,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Stock Down 0.0%

NASDAQ PCVX opened at $61.16 on Friday. The stock has a market capitalization of $9.10 billion, a PE ratio of -8.02 and a beta of 1.22. The company has a 50 day moving average price of $58.22 and a two-hundred day moving average price of $56.20. Vaxcyte, Inc. has a 12-month low of $30.81 and a 12-month high of $65.00.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same quarter last year, the business posted ($1.22) EPS. As a group, equities analysts anticipate that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 2,000 shares of the firm’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $55.65, for a total transaction of $111,300.00. Following the transaction, the chief executive officer directly owned 133,215 shares in the company, valued at $7,413,414.75. This trade represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 3,477 shares of the business’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $61.07, for a total value of $212,340.39. Following the completion of the sale, the chief operating officer directly owned 155,041 shares of the company’s stock, valued at $9,468,353.87. This represents a 2.19% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 121,873 shares of company stock valued at $6,671,730. Company insiders own 3.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PCVX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Vaxcyte has an average rating of “Moderate Buy” and a consensus target price of $86.00.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.